{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:42:58Z","timestamp":1763642578427,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"am","delay-in-days":398,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.rmr.2018.09.003","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T10:10:08Z","timestamp":1550916608000},"page":"405-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Place des biomarqueurs dans la prise en charge des infections pulmonaires"],"prefix":"10.1016","volume":"36","author":[{"given":"M.","family":"Neuville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Cally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bouadma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2018.09.003_bib0335","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(15)61340-X","article-title":"Global, regional, and national disability-adjusted life years (DALYs) for 306\u00a0diseases and injuries and healthy life expectancy (HALE) for 188\u00a0countries, 1990\u20132013: quantifying the epidemiological transition","volume":"386","author":"GBD 2013\u00a0DALYs and HALE Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2018.09.003_bib0340","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","article-title":"Community-acquired pneumonia","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2018.09.003_bib0345","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201510060","article-title":"In the clinic: community-acquired pneumonia","volume":"163","author":"Niederman","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0350","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0355","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.rmr.2018.09.003_bib0360","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/cc8872","article-title":"Sepsis biomarkers: a review","volume":"14","author":"Pierrakos","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.rmr.2018.09.003_bib0365","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.52.4.561","article-title":"Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus","volume":"52","author":"Tillett","year":"1930","journal-title":"J Exp Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0370","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1086\/421997","article-title":"Serum procalcitonin and c-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis","volume":"39","author":"Simon","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0375","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ccc.2006.03.003","article-title":"Markers for sepsis diagnosis: what is useful?","volume":"22","author":"Reinhart","year":"2006","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.rmr.2018.09.003_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(02)00047-X","article-title":"Procalcitonin as a marker of sepsis","volume":"20","author":"Carrol","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.rmr.2018.09.003_bib0385","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1128\/JCM.00655-10","article-title":"Use of plasma procalcitonin levels as an adjunct to clinical microbiology","volume":"48","author":"Gilbert","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2018.09.003_bib0390","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0140-6736(93)90277-N","article-title":"High serum procalcitonin concentrations in patients with sepsis and infection","volume":"341","author":"Assicot","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2018.09.003_bib0395","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1183\/09031936.00166106","article-title":"Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators","volume":"30","author":"Christ-Crain","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2018.09.003_bib0400","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00011-012-0439-5","article-title":"Immune regulation of procalcitonin: a biomarker and mediator of infection","volume":"61","author":"Matwiyoff","year":"2012","journal-title":"Inflamm Res"},{"key":"10.1016\/j.rmr.2018.09.003_bib0405","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1093\/cid\/cir050","article-title":"Procalcitonin as a biomarker in respiratory tract infection","volume":"52","author":"Gilbert","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0410","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1542\/peds.2006-3283","article-title":"Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants","volume":"120","author":"Melendi","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.rmr.2018.09.003_bib0415","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/CCM.0B013E318165BABB","article-title":"Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations","volume":"36","author":"Becker","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0420","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.4049\/jimmunol.164.10.4991","article-title":"Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes","volume":"164","author":"Bouchon","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.rmr.2018.09.003_bib0425","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1183\/09031936.02.00295102","article-title":"Systemic cytokine levels in community-acquired pneumonia and their association with disease severity","volume":"20","author":"Antunes","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2018.09.003_bib0430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1440-1843.2007.01189.x","article-title":"Pleural fluid interleukin-8\u00a0and C-reactive protein for discriminating complicated non-purulent from uncomplicated parapneumonic effusions","volume":"13","author":"Porcel","year":"2008","journal-title":"Respirol"},{"key":"10.1016\/j.rmr.2018.09.003_bib0435","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1309\/AJCPDC7PS8TIPBXP","article-title":"Utility of measurement of interleukin-1\u00df and interleukin-8\u00a0in the diagnosis of complicated parapneumonic pleural effusions","volume":"142","author":"San Jos\u00e9","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rmr.2018.09.003_bib0440","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1378\/chest.125.4.1192","article-title":"C-reactive protein in pneumonia: let me try again","volume":"125","author":"Luna","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.09.003_bib0445","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1378\/chest.125.4.1335","article-title":"Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia","volume":"125","author":"Almirall","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.09.003_bib0450","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2334-7-10","article-title":"Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia","volume":"7","author":"M\u00fcller","year":"2007","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0455","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/ajrccm.164.3.2009052","article-title":"Diagnostic value of procalcitonin, interleukin-6, and interleukin-8\u00a0in critically ill patients admitted with suspected sepsis","volume":"164","author":"Harbarth","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0460","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(04)15591-8","article-title":"Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial","volume":"363","author":"Christ-Crain","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2018.09.003_bib0465","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1164\/rccm.200512-1922OC","article-title":"Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial","volume":"174","author":"Christ-Crain","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0470","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1378\/chest.06-1500","article-title":"Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy","volume":"131","author":"Stolz","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.09.003_bib0475","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.2009.1297","article-title":"Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial","volume":"302","author":"Schuetz","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2018.09.003_bib0480","first-page":"CD007498","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"9","author":"Schuetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2018.09.003_bib0485","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11908-014-0451-8","article-title":"Biomarkers for community-acquired pneumonia in the emergency department","volume":"16","author":"Florin","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.rmr.2018.09.003_bib0490","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00508-006-0563-8","article-title":"Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia","volume":"118","author":"Jereb","year":"2006","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.rmr.2018.09.003_bib0495","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s150100050049","article-title":"Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis","volume":"28","author":"Hedlund","year":"2000","journal-title":"Infection"},{"key":"10.1016\/j.rmr.2018.09.003_bib0500","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/cix317","article-title":"Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia","volume":"65","author":"Self","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0505","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa031544","article-title":"Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia","volume":"350","author":"Gibot","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0510","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.CCM.0000257480.45965.8C","article-title":"Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1\u00a0in community-acquired pneumonia","volume":"35","author":"M\u00fcller","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0515","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e318157aced","article-title":"The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230\u00a0children","volume":"27","author":"Flood","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.rmr.2018.09.003_bib0520","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.annemergmed.2012.05.027","article-title":"Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta-analysis","volume":"60","author":"Yo","year":"2012","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0525","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1542\/peds.112.5.1054","article-title":"Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center","volume":"112","author":"Galetto-Lacour","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.rmr.2018.09.003_bib0530","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/01.inf.0000095197.72976.4f","article-title":"Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection","volume":"22","author":"Prat","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.rmr.2018.09.003_bib0535","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ppul.10201","article-title":"Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings","volume":"35","author":"Korppi","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2018.09.003_bib0540","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/INF.0b013e31829ba62a","article-title":"Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal community-acquired pneumonia in children","volume":"32","author":"Galetto-Lacour","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.rmr.2018.09.003_bib0545","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1465-9921-8-30","article-title":"Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review","volume":"8","author":"Puhan","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2018.09.003_bib0550","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/1471-2334-13-596","article-title":"Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial","volume":"13","author":"Tang","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0555","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1378\/chest.10-1747","article-title":"Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD","volume":"139","author":"Bafadhel","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2018.09.003_bib0560","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7150\/ijms.4972","article-title":"Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Ding","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.rmr.2018.09.003_bib0565","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2018.09.003_bib0570","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/archinte.168.18.2000","article-title":"Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care","volume":"168","author":"Briel","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0575","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1469-0691.2009.02856.x","article-title":"Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia","volume":"15","author":"Hohenthal","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2018.09.003_bib0580","doi-asserted-by":"crossref","first-page":"R92","DOI":"10.1186\/cc6105","article-title":"Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course","volume":"11","author":"Coelho","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.rmr.2018.09.003_bib0585","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/01.CCM.0000226413.54364.36","article-title":"Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis","volume":"34","author":"Uzzan","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0590","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1473-3099(07)70052-X","article-title":"Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis","volume":"7","author":"Tang","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.rmr.2018.09.003_bib0595","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1097\/01.CCM.0000239116.01855.61","article-title":"Procalcitonin increase in early identification of critically ill patients at high risk of mortality","volume":"34","author":"Jensen","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0600","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00134-005-0047-8","article-title":"Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia","volume":"32","author":"Boussekey","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0605","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MD.0b013e318190f444","article-title":"Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study","volume":"87","author":"Johnstone","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rmr.2018.09.003_bib0610","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0032-1315644","article-title":"Long-term mortality after pneumonia","volume":"33","author":"Mortensen","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0615","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jama.2014.18229","article-title":"Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease","volume":"313","author":"Corrales-Medina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2018.09.003_bib0620","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0625","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1183\/09031936.00049111","article-title":"Is community-acquired pneumonia an independent risk factor for cardiovascular disease?","volume":"39","author":"Singanayagam","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2018.09.003_bib0630","first-page":"CD012252","article-title":"Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: an overview of systematic reviews","volume":"9","author":"Tonkin-Crine","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2018.09.003_bib0635","first-page":"CD003539","article-title":"Interventions to improve antibiotic prescribing practices in ambulatory care","author":"Arnold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2018.09.003_bib0640","first-page":"CD010130","article-title":"Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care","volume":"11","author":"Aabenhus","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2018.09.003_bib0645","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1802670","article-title":"Procalcitonin-guided use of antibiotics for lower respiratory tract infection","volume":"379","author":"Huang","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0650","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1515\/cclm-2014-1015","article-title":"Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective","volume":"53","author":"Schuetz","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0655","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11606-013-2679-7","article-title":"Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults","volume":"29","author":"Michaelidis","year":"2014","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.rmr.2018.09.003_bib0330","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1183\/09031936.00163309","article-title":"Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection","volume":"36","author":"Burkhardt","year":"2010","journal-title":"Eur Respir J"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842519300026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842519300026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:19:09Z","timestamp":1760105949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842519300026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0761842519300026"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2018.09.003","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place des biomarqueurs dans la prise en charge des infections pulmonaires","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of SPLF.","name":"copyright","label":"Copyright"}]}}